PHILADELPHIA, PA — Virion Therapeutics LLC reported data showing its experimental hepatitis B immunotherapy VRON-0200 generated sustained immune responses in chronically infected patients following a ...
(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果